An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia An open-label randomized controlled study
Latest Information Update: 04 Nov 2022
Price :
$35 *
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- 30 Oct 2022 Status changed from recruiting to completed.
- 25 Sep 2020 New trial record